Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 132 publications.

Leonard C, Unsworth H, Warttig S, Gildea L, Mordin M, Ling C. HTA considerations for large language models in healthcare. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Leonard C, Bhogal P, Menon AP, Ling C, Mordin M. HTA requirements for medical technologies in Spain. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, van Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV. [abstract] J Manag Care Spec Pharm. 2024 Oct; 30(10-c):S155. Previously presented at the 10th Congress of the European Academy of Neurology.

Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564

Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the 10th Congress of the European Academy of Neurology; June 29, 2024. Helenski, Finland. [abstract] Eur J Neurol. 2024 Jun; 31(Suppl 1).

Blumenfeld A, Mordin M, Kosa K, Castro C, Stokes J, Shah D, Buse DC. Exploring the experience of neck pain in individuals with episodic migraine. Poster presented at the International Neurotoxin Association 7th International Conference (TOXINS 2024); January 17, 2024. Barcelona, Spain. Previously presented at the American Academy of Neurology (AAN) 2023 Annual Meeting.

Blumenfeld A, Mordin M, Kosa K, Castro C, Stokes J, Shah D, Buse DC. Exploring the experience of neck pain in individuals with episodic migraine. Poster presented at the 17th European Headache Congress (EHC) 2023; December 6, 2023. Barcelona, Spain. Previously presented at the American Academy of Neurology (AAN) 2023 Annual Meeting.

Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Warttig S, Hartley L, Ling C. Understanding how health technology assessment bodies select medical technology for review: results of an online survey. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S432. doi: 10.1016/j.jval.2023.09.2258

D'Souza V, Gildea L, Mordin M, Long J, Kinderås M, Ling C, Warttig S, Hartley L. Differences and similarities of health economic evaluation for medical technologies by HTA bodies. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S438. doi: 10.1016/j.jval.2023.09.2287

Mordin M, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Warttig S, Hartley L. What evidence should medical technology companies expect HTA bodies to review? Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S431. doi: 10.1016/j.jval.2023.09.2254

Mordin M, Warttig S, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Hartley L. Digging into the medical technology HTA process in Tunisia. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S429. doi: 10.1016/j.jval.2023.09.2242

Kinderås M, Gildea L, Mordin M, Long J, D'Souza V, Ling C, Warttig S, Hartley L. Submission process and requirements of Nordic health technology assessment organisations for medical technologies: results of an online survey. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S435. doi: 10.1016/j.jval.2023.09.2272

Hartley L, Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Ling C, Warttig S. Does real-world evidence play a role in decision-making by HTA bodies for medical technologies? Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S434-5. doi: 10.1016/j.jval.2023.09.2271

Cella D, Wen PY, Ervin C, Vallow S, Gilloteau I, DeMuro C, Mordin M, Agostinho AC, Dine J. Understanding the patient experience and treatment benefits in patients with non–small-cell lung cancer with brain metastasis. Cancer Med. 2023 Jun 12;12(12):13637-48. doi: 10.1002/cam4.5975

Mordin M, Castro C, Gnanasakthy A. Trends in the inclusion of patient reported outcomes in oncology clinical trials: analysis of clinicaltrials.gov (2013-2022). Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S325. doi: 10.1016/j.jval.2023.03.1852

Mordin M, Gildea LJ, Warttig S, Costello J, D'Souza V, Kinderås M, Ling C, Marcano Belisario J. HTA processes for medical technologies across the world – are all hurdles the same? Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S272-3. doi: 10.1016/j.jval.2023.03.1503

Blumenfeld AM, Mordin M, Kosa KM, Castro CV, Stokes J, Shah D, Buse DC. Exploring the experience of neck pain in individuals with episodic migraine. Poster presented at the American Academy of Neurology (AAN) 2023 Annual Meeting; April 23, 2023. Boston, MA.

Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Petrillo Billet J. Driving outcomes in mild cognitive impairment/Alzheimer's disease - a review of association between driving simulator measures and clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Billet JP. Impact of Huntington's disease on driving: a review of driving simulator measures and association with clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Salas M, Mordin M, Castro C, Islam Z, Tu N, Hackshaw MD. Health-related quality of life in women with breast cancer: a review of measures. BMC Cancer. 2022 Jan 15;22(1):66. doi: 10.1186/s12885-021-09157-w

Mordin M, Parrish W, Masaquel C, Bisson B, Copley-Merriman K. Intra-articular hyaluronic acid for osteoarthritis of the knee in the United States: a systematic review of economic evaluations. Clin Med Insights Arthritis Musculoskelet Disord. 2021 Nov 19;14:1-13. doi: 10.1177/11795441211047284

Copley-Merriman C, Mordin M. Use of pragmatic clinical trials in reimbursement decisions. In: Girman, CJ, Ritchey, ME, editors. Pragmatic randomized clinical trials: using primary data collection and electronic health records. 1st ed. Waltham: MA. Academic Press; 2021. p.445-60.

Fernandez M, Mordin M, Neighbors M, Tzivelekis S. A targeted literature review on the burden of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Poster presented at the 2020 Virtual German Neurological Society (DGN) Congress; November 4, 2020. Previously presented at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Conference..

Castro C, Mordin M, Islam Z, Tu N, Hackshaw MD, Salas M. A review of non-disease specific health-related quality of life measures with reliability and validity evidence in patients with breast cancer. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S81.

Wronski SL, Mordin M, Kelley K, Anguiano RH, Classi P, Shen E, Manaker S. The role of noninvasive endpoints in predicting long-term outcomes in pulmonary arterial hypertension. Lung. 2020 Feb;198(1):65-86. doi: 10.1007/s00408-019-00289-2

Fernandez M, Mordin M, Neighbors M, Boudjemia K, Tzivelekis S. A targeted literature review on the burden of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Poster presented at the 21st Congress of the Société Française de Neurologie Pédiatrique (SFNP); January 2020. Toulouse, France. Previously presented at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Conference.

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Hur P. Evaluation of the feasibility of a web-based survey to assess patient-reported symptom improvement and treatment satisfaction among patients with psoriatic arthritis receiving Secukinumab. Clin Drug Invest. 2019 Dec;39(12):1205-12. doi: 10.1007/s40261-019-00856-8

Fernandez MM, Mordin M, Hadacek MB, Moecklinghoff C, Vloeberghs E, El khoury A, Tronczynski K. PrEP reimbursement and access in Europe: 2019 update. Poster presented at the 17th European AIDS Conference; November 2019. Basel, Switzerland. [abstract] HIV Med. 2019 Nov 6; 20(Suppl. 9):240. doi: 10.1111/hiv.12814

Fernandez M, Mordin M, Neighbors M, Tzivelekis S. A targeted literature review on the burden of chronic inflammatory demyelinating polyneuropathy. Poster presented at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Conference; October 16, 2019. Austin, TX. [abstract] Muscle Nerve. 2019 Sep; p.112.

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Chirila C, Park Y. A pilot study to assess the feasibility of a web-based survey to examine patient-reported symptoms and satisfaction in patients with ankylosing spondylitis receiving secukinumab. Drugs Real World Outcomes. 2019 Jun;6(2):83-91. doi: 10.1007/S40801-019-0154-4

Khan S, Mordin M, Barrows SB, Copley-Merriman K. Similarities & differences in Global Value Dossier (GVD) and Academy of Managed Care Pharmacy (AMCP) dossier development. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA.

Ritchey ME, Mordin M. A consolidated framework for collaboration in RWE generation for a medical product. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA.

Mordin M, Castro C, Buck PM, Fernandez MM, Hollis KA, Ritchey ME. European “real-world” evidence for drugs and devices: 2017 literature reviewed. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Coles T, Williams V, Dwyer K, Mordin M. Psychometric evaluation of the patient's knee implant performance questionnaire. Value Health. 2018 Nov;21(11):1305-12. doi: 10.1016/j.jval.2018.05.006

Ritchey ME, Castro C, Buck PM, Fernandez M, Hollis K, Mordin M. A review of 2017 “real-world” evidence literature in Asia. Poster presented at ISPE's 11th Asian Conference on Pharmacoepidemiology; October 2018. Xi’an, China.

Kelley K, Mordin M, Wronski S, Classi P. The relationship between non-invasive endpoints and long-term outcomes in pulmonary arterial hypertension: six-minute walk, functional class, and brain natriuretic peptide. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2018 Oct; 24(10-a):S61.

Ritchey ME, Buck P, Castro C, Fernandez M, Hollis K, Mordin M. "Real-world" evidence for drugs and devices: 2017 literature reviewed. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):410-1. doi: 10.1002/pds.4629

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E, Park Y. Treatment experience and satisfaction in ankylosing spondylitis patients treated with secukinumab: results from a US web-based survey. Poster presented at the 2018 Annual European Congress of Rheumatology (EULAR); June 16, 2018. Amsterdam, The Netherlands.

Mordin M, Fernandez M, Pearson I, Copley-Merriman K, Mcbride D. Similarities and differences in European HTA evidence requirements: one for all or one for none? Presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.

Fernandez MM, Khan S, Mordin M, Copley-Merriman C, Mcbride D. Comparing literature review requirements for reimbursement submissions across the globe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.732

Mordin M, Buck PM, Castro C, Fernandez MM, Hollis KA, Ritchey ME. What does "Real World" evidence mean? A review of 2017 literature. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.736

Magrey M, Wolin DL, Mordin MM, McLeod LD, Davenport EK, Hur P. US patient satisfaction with Secukinumab treatment among patients with both psoriatic arthritis and psoriasis: data from a web-based survey. Poster presented at the 2018 Winter Clinical Dermatology Conference; January 2018. Hawaii. [abstract] Skin: the journal of cutaneous medicine. 2018 Feb 23; 2(2018). doi: 10.25251/skin.2.supp.25

Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Trea. 2017 Sep;28(6):492-9. doi: 10.1080/09546634.2017.1307464

Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tyring S. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Trea. 2017 Aug;28(5):384-9.

Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043

Gnanasakthy A, Mordin M, Evans E, Doward L, DeMuro C. A review of patient-reported outcome labeling in the United States (2011-2015). Value Health. 2017;20(3):420-9. doi: 10.1016/j.jval.2016.10.006

Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides better relief from psoriasis impact on personal relationships than etanercept. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.

Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo. Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.

Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.